|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1999-6-23
|
|
pubmed:abstractText |
The neurologic pathologies for which contrast-enhanced MRI is indicated are often accompanied by a disruption of the blood-brain barrier (BBB), which allows the contrast agent to come into contact with the nervous tissue. Thus, assessment of the neurologic safety for a new contrast agent is of crucial importance. The objective of this study was to assess the neurotolerability of the new MRI contrast agent gadobenate dimeglumine using EEG in the presence of focal lesions of the BBB.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0020-9996
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
34
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
262-7
|
|
pubmed:dateRevised |
2009-11-11
|
|
pubmed:meshHeading |
pubmed-meshheading:10196717-Animals,
pubmed-meshheading:10196717-Blood-Brain Barrier,
pubmed-meshheading:10196717-Brain,
pubmed-meshheading:10196717-Brain Ischemia,
pubmed-meshheading:10196717-Contrast Media,
pubmed-meshheading:10196717-Electroencephalography,
pubmed-meshheading:10196717-Gadolinium,
pubmed-meshheading:10196717-Magnetic Resonance Imaging,
pubmed-meshheading:10196717-Male,
pubmed-meshheading:10196717-Meglumine,
pubmed-meshheading:10196717-Organometallic Compounds,
pubmed-meshheading:10196717-Rats
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Neurotolerability of gadobenate dimeglumine in a rat model of focal brain ischemia: EEG evaluation.
|
|
pubmed:affiliation |
Milano Research Center, Bracco SpA, Italy.
|
|
pubmed:publicationType |
Journal Article
|
